Research ArticleCancer

CD99 is a therapeutic target on disease stem cells in myeloid malignancies

See allHide authors and affiliations

Science Translational Medicine  25 Jan 2017:
Vol. 9, Issue 374, eaaj2025
DOI: 10.1126/scitranslmed.aaj2025

Article Information

vol. 9 no. 374

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication October 13, 2015
  • Resubmitted September 12, 2016
  • Accepted for publication November 22, 2016

Author Information

  1. Stephen S. Chung1,2,
  2. William S. Eng1,
  3. Wenhuo Hu1,
  4. Mona Khalaj1,3,
  5. Francine E. Garrett-Bakelman4,
  6. Montreh Tavakkoli1,
  7. Ross L. Levine1,2,
  8. Martin Carroll5,
  9. Virginia M. Klimek2,
  10. Ari M. Melnick4 and
  11. Christopher Y. Park1,6,*,
  1. 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  2. 2Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  3. 3Weill Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA.
  4. 4Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell School of Medicine, New York, NY 10065, USA.
  5. 5Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
  6. 6Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  1. Corresponding author. Email: christopher.park{at}nyumc.org
  • * Present address: Department of Pathology, New York University School of Medicine, New York, NY 10016, USA.

AltMetrics

Article usage

AbstractFullPDF
Jan 20174390217424
Feb 20171944167472
Mar 201758985170
Apr 201740490111
May 20173423067
Jun 20172553241
Jul 20172312855
Aug 20172683355
Sep 20171401731